learningmedicine

Monday, November 10, 2025

The Endotype-Driven Sepsis Trial: A New Research Paradigm

A Review for Critical Care Postgraduates

Dr Neeraj Manikath , claude.ai

Abstract

Despite decades of research and over 100 failed randomized controlled trials, sepsis remains a leading cause of mortality in intensive care units worldwide. The repeated failure of promising therapies in phase III trials has led to a fundamental rethinking of sepsis research methodology. This review explores the emerging paradigm of endotype-driven sepsis trials, which recognizes sepsis as a heterogeneous syndrome requiring precision medicine approaches. We examine why traditional "one-size-fits-all" trials have failed, how platform trials enable adaptive, efficient study designs, and the role of biomarker-enriched enrollment in matching patients to therapies. Understanding these concepts is essential for the next generation of critical care physicians who will both conduct and interpret modern sepsis research.

Introduction

Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, affects approximately 49 million people and causes 11 million deaths annually worldwide.[1] Despite improvements in supportive care, sepsis mortality remains unacceptably high at 20-30% for sepsis and up to 40-50% for septic shock.[2] More frustratingly, the last four decades have witnessed a graveyard of failed sepsis therapeutics—from anti-endotoxin antibodies to activated protein C, from anti-TNF strategies to countless immunomodulatory agents.[3]

This litany of failures has forced a paradigm shift. We now recognize that sepsis is not a single disease but a heterogeneous syndrome with multiple underlying biological phenotypes, or "endotypes."[4] Just as oncology abandoned treating "cancer" as a monolithic entity in favor of targeted therapies based on tumor genetics, sepsis research must evolve toward precision medicine approaches that match specific therapies to biologically defined patient subgroups.

This review examines three pillars of this new research paradigm: understanding why previous trials failed, designing adaptive platform trials that can efficiently test multiple interventions, and using biomarkers to enrich trial enrollment with patients most likely to benefit.

Moving Beyond "One-Size-Fits-All" Trials: Why Previous Sepsis Drug Trials Failed and How Endotypes Change the Game

The Historical Landscape of Failure

The history of sepsis drug development reads like a medical tragedy. Between 1991 and 2020, more than 100 phase III randomized controlled trials of sepsis therapeutics failed to demonstrate benefit, and in some cases caused harm.[5] Notable examples include:

Anti-endotoxin strategies (1991-1998): Multiple monoclonal antibodies targeting lipopolysaccharide failed despite sound biological rationale.[6]
Anti-TNF therapies (1993-1996): Despite success in animal models, neutralizing tumor necrosis factor showed no benefit and potential harm in human trials.[7]
Activated Protein C (drotrecogin alfa) (2001-2011): Initially approved based on the PROWESS trial showing mortality reduction, it was withdrawn after the PROWESS-SHOCK trial failed to confirm benefit and raised safety concerns about bleeding.[8]
Anti-TLR4 therapy (2013): Eritoran, a Toll-like receptor 4 antagonist, failed in the ACCESS trial despite promising preclinical data.[9]
Corticosteroids: Multiple trials over three decades showed conflicting results until recent studies suggested benefit in specific subgroups.[10]

Pearl: The activated protein C story exemplifies the dangers of heterogeneity in sepsis trials. Post-hoc analyses suggested benefit was confined to patients with severe disease and high inflammatory markers—a biomarker-defined subgroup.[8]

Why Did These Trials Fail?

The causes of failure are multifactorial but increasingly well-understood:

1. Biological Heterogeneity

Sepsis encompasses patients with vastly different underlying pathophysiology. Some patients exhibit hyperinflammation with cytokine storm, while others demonstrate immunosuppression with impaired pathogen clearance.[11] Treating these opposing endotypes with the same intervention is akin to using chemotherapy for both rapidly dividing and quiescent tumors.

Seymour et al. (2019) used machine learning to identify four sepsis phenotypes (α, β, γ, δ) with distinct clinical outcomes and host-response patterns.[12] The δ phenotype showed high inflammatory markers and mortality of 40%, while the α phenotype had lower inflammation and 5% mortality. A therapy targeting inflammation would predictably show different effects across these phenotypes.

2. Timing and Disease Stage Mismatch

Sepsis pathophysiology evolves dynamically over hours and days. Early sepsis may be characterized by pro-inflammatory mediators, while late sepsis often features immunosuppression.[13] Administering immunosuppressive therapy to a patient in the hyperinflammatory phase, or vice versa, may be harmful. Traditional trials enrolled patients based on clinical criteria (e.g., meeting Sepsis-3 definitions) without regard to disease stage or biological phenotype.

Oyster: The VANISH trial (2016) comparing vasopressin versus norepinephrine showed no overall mortality benefit, but post-hoc analysis revealed vasopressin reduced mortality in patients with lower baseline cortisol levels.[14] The treatment effect was hidden in the overall heterogeneous population.

3. Inadequate Preclinical Models

Most sepsis trials were based on animal models, typically young, healthy rodents with cecal ligation and puncture or endotoxin injection. These models poorly replicate the complexity of human sepsis, which occurs predominantly in elderly patients with comorbidities and varying pathogens.[15]

4. Statistical Considerations

When treatment effects are heterogeneous, overall trial results may show null findings even if substantial benefit exists in subgroups. Conversely, chance findings in heterogeneous populations may lead to false-positive results that fail to replicate (as with activated protein C).

The Endotype Solution

An endotype is a subtype of a condition defined by a distinct pathobiological mechanism.[16] In sepsis, proposed endotypes include:

Hyperinflammatory endotype: Elevated pro-inflammatory cytokines (IL-6, IL-8, TNF-α), high C-reactive protein, associated with cytokine storm and early organ failure.
Immunosuppressive endotype: Low HLA-DR expression on monocytes, lymphopenia, elevated IL-10, impaired pathogen clearance.
Endotheliopathic endotype: Elevated markers of endothelial injury (angiopoietin-2, syndecan-1), associated with capillary leak and organ dysfunction.[17]

Hack: Think of endotypes by asking three questions: (1) Is the immune system overactive or underactive? (2) Is there primary endothelial injury? (3) What is the source and type of infection? These questions guide rational therapy selection.

Matching interventions to endotypes makes biological sense:

Anti-inflammatory therapies (e.g., anti-IL-6, corticosteroids) for hyperinflammatory phenotypes
Immune-stimulating therapies (e.g., GM-CSF, anti-PD-1) for immunosuppressed phenotypes[18]
Anticoagulant or endothelial-protective therapies for coagulopathic/endotheliopathic phenotypes

Evidence for Endotype-Specific Effects

Growing evidence supports endotype-stratified treatment:

VANISH trial post-hoc analysis: Vasopressin reduced mortality in patients with relative adrenal insufficiency (cortisol <10 μg/dL).[14]
CITRIS-ALI trial: Vitamin C showed mortality benefit in patients with higher baseline inflammatory markers.[19]
HARP-2 trial: Heparin showed heterogeneous treatment effects based on coagulation profiles.[20]
Sepsis endotyping studies: Wong et al. identified pediatric septic shock endotypes with 100-fold differences in mortality, suggesting vastly different treatment needs.[21]

Pearl: Endotype-driven trials don't just improve success rates—they reduce sample sizes, costs, and time to approval by focusing on biologically rational target populations.

Platform Trials: Designing Adaptive Studies That Can Test Multiple Therapies Against Different Sepsis Subphenotypes Simultaneously

The Platform Trial Revolution

A platform trial is a master protocol designed to evaluate multiple therapies (or therapy combinations) for a single disease using shared infrastructure, with the ability to add or drop treatment arms based on prespecified rules.[22] Unlike traditional two-arm RCTs where each new drug requires a new trial, platform trials operate as perpetual studies that continuously test new interventions.

Key Features of Platform Trials

1. Shared Control Arm

All investigational therapies are compared against a common control group (usually standard of care), dramatically improving efficiency. For example, testing five therapies would traditionally require five separate trials with five control groups (potentially 2,500+ patients total). A platform trial uses one control group, requiring fewer patients overall.[23]

2. Response-Adaptive Randomization (RAR)

As data accumulates, randomization probabilities shift to favor better-performing arms. If Therapy A shows early signals of benefit while Therapy B appears harmful, more patients are allocated to Therapy A, and Therapy B may be dropped for futility.[24] This is ethically superior to fixed randomization and statistically efficient.

Oyster: RAR does not introduce bias if implemented correctly with appropriate statistical adjustments. The final analysis accounts for changing randomization probabilities using weighted estimators.[25]

3. Biomarker-Stratified Randomization

Patients can be stratified by endotype at enrollment, with therapies assigned preferentially to their target endotype. A patient identified as hyperinflammatory might be randomized among anti-inflammatory interventions, while an immunosuppressed patient enters the immune-stimulation treatment arms.

4. Seamless Phase II/III Design

Platform trials can begin with phase II dose-finding, then seamlessly transition promising therapies to phase III efficacy testing within the same protocol, eliminating years of delay between phases.[26]

5. Master Protocol Efficiency

A single IRB approval, unified eligibility criteria, shared data monitoring, and common endpoint definitions reduce administrative burden and ensure consistency across treatment comparisons.

Real-World Examples

REMAP-CAP (Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia)

REMAP-CAP is the exemplar sepsis platform trial, designed to test multiple interventions for severe pneumonia and sepsis.[27] During the COVID-19 pandemic, it rapidly identified effective therapies:

Corticosteroids: Demonstrated mortality benefit in severe COVID-19 pneumonia within months.[28]
IL-6 antagonists: Showed benefit when combined with corticosteroids in critically ill patients.[29]
Anticoagulation: Identified therapeutic-dose heparin benefit in moderately ill but harm in severely ill patients—a clear example of heterogeneity of treatment effect.[30]

REMAP-CAP's adaptive design allowed it to answer multiple questions simultaneously while traditional RCTs were still enrolling. It has now expanded to test therapies for bacterial sepsis with endotype-stratified domains.

Hack: When reading platform trial results, pay attention to the "domain" structure. Each domain tests interventions for a specific biological mechanism (e.g., immune modulation domain, anticoagulation domain), allowing focused questions within the larger trial.

ADAPT-Sepsis

This UK-based platform trial aims to test immunomodulatory therapies in endotype-defined sepsis populations. It uses baseline biomarkers (ferritin, HLA-DR expression, neutrophil-to-lymphocyte ratio) to assign patients to hyperinflammatory versus immunosuppressed categories, then randomizes within those groups.[31]

Statistical Innovations

Platform trials employ sophisticated statistical methods:

Bayesian adaptive designs: Update treatment effect estimates continuously as data accrues, allowing earlier stopping for benefit or futility.[32]
Borrowing across arms: Information from completed arms can inform ongoing arms if therapies share mechanisms.
Master protocols with multiple estimands: Can answer questions about overall benefit, subgroup-specific effects, and optimal treatment sequences simultaneously.[33]

Pearl: Bayesian statistics in platform trials isn't about prior beliefs—it's about efficiently updating knowledge. The posterior probability of benefit (e.g., "95% probability that Therapy X reduces mortality by >5%") is often more clinically interpretable than a p-value.

Challenges and Solutions

Challenge 1: Complexity

Platform trials require sophisticated data infrastructure and real-time analytics.

Solution: Many leverage electronic health records and automated data capture. Predefined statistical analysis plans are coded in advance.

Challenge 2: Investigator and Patient Understanding

Explaining adaptive randomization and multiple simultaneous interventions is challenging.

Solution: Standardized consent processes and investigator training programs. REMAP-CAP demonstrated that well-educated sites can implement complex protocols successfully.

Challenge 3: Regulatory Acceptance

Drug approval typically requires two pivotal RCTs. Will regulators accept platform trial results?

Solution: FDA and EMA have issued guidance accepting platform trials when properly designed. REMAP-CAP results led to therapy approvals, validating the approach.[34]

Oyster: Platform trials aren't just for big diseases. Small rare disease communities use them because sharing controls makes research feasible with limited patients.[35]

Biomarker-Enriched Enrollment: Selecting Patients for Trials Based on Inflammatory or Immunosuppressive Profiles, Not Just Clinical Criteria

The Rationale for Biomarker Enrichment

Biomarker-enriched enrollment involves selecting trial participants based on biological characteristics that predict treatment response, not merely clinical syndrome definitions.[36] This approach:

Increases treatment effect size by excluding patients unlikely to respond
Reduces sample size requirements and trial costs
Minimizes exposure of non-responders to potential toxicity
Accelerates regulatory approval by demonstrating clear benefit in the target population

In sepsis, where heterogeneity is extreme, biomarker enrichment may be essential for trial success.

Categories of Sepsis Biomarkers

1. Inflammatory Biomarkers

These identify hyperinflammatory states:

Pro-inflammatory cytokines: IL-6 (>1000 pg/mL suggests hyperinflammation), IL-8, TNF-α[37]
Acute phase reactants: C-reactive protein (CRP >150 mg/L), procalcitonin (PCT >10 ng/mL)
Ferritin: Markedly elevated (>2000 μg/L) in macrophage activation syndromes
Soluble urokinase plasminogen activator receptor (suPAR): Elevated in systemic inflammation[38]

Pearl: IL-6 is emerging as the gold-standard inflammatory biomarker. It's measurable within hours using point-of-care assays, correlates with mortality, and is increasingly used for trial enrollment.[39]

2. Immunosuppression Biomarkers

These identify patients with impaired immune responses:

HLA-DR expression on monocytes (mHLA-DR): <30% expression indicates immunoparalysis. Flow cytometry measurement is feasible in 4-6 hours.[40]
Lymphocyte count: Absolute lymphocyte count <600 cells/μL suggests immunosuppression
IL-10: Elevated anti-inflammatory cytokine indicates immune exhaustion
PD-1/PD-L1 expression: Checkpoint inhibitor expression on immune cells[41]
Ex vivo TNF production: Reduced lipopolysaccharide-stimulated TNF production indicates endotoxin tolerance[42]

Hack: For bedside assessment, consider simple composite scores: high neutrophil-to-lymphocyte ratio (>20) + low absolute lymphocyte count (<500) + prolonged sepsis (>3 days) = likely immunosuppressed. This doesn't replace formal biomarkers but guides empiric thinking.

3. Endothelial and Coagulation Biomarkers

These identify endotheliopathy and coagulopathy:

Angiopoietin-2 (Ang-2): Marker of endothelial activation and leak, correlates with mortality[43]
Syndecan-1: Glycocalyx degradation marker indicating capillary leak
Thrombomodulin: Elevated in endothelial injury
D-dimer, fibrinogen, antithrombin: Identify consumptive coagulopathy[44]

4. Organ-Specific Biomarkers

Cardiac: NT-proBNP, troponin (identify septic cardiomyopathy)
Renal: Neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1)
Hepatic: Bilirubin, lactate (metabolic dysfunction)[45]

Practical Implementation

Point-of-Care Testing

For biomarker enrichment to work in acute sepsis trials, results must be available within hours. Emerging technologies enable this:

Rapid IL-6 assays: Results in 20-30 minutes using immunoassays
Flow cytometry: mHLA-DR measurement in 4-6 hours at experienced centers
Multiplex platforms: Simultaneous measurement of 10+ biomarkers using microfluidics[46]

Oyster: Don't let perfect be the enemy of good. Even simple biomarkers like CRP and lymphocyte count, available within 1 hour, provide valuable enrichment. The CITRIS-ALI trial used baseline CRP to stratify patients post-hoc and found significant heterogeneity.[19]

Case Studies in Biomarker-Enriched Trials

1. IL-6 Blockade Trials

The IMMUNECOV trial tested tocilizumab (anti-IL-6 receptor) in COVID-19 pneumonia patients with elevated inflammatory markers (CRP >75 mg/L). Enrolling only patients with documented hyperinflammation increased the treatment effect, showing significant mortality reduction.[47]

2. GM-CSF for Immunosuppression

The GRID trial is testing granulocyte-macrophage colony-stimulating factor (GM-CSF) in sepsis patients with documented immunosuppression (low mHLA-DR <30%). By excluding patients without immunoparalysis, the trial enriches for those most likely to benefit from immune stimulation.[48]

3. Antithrombin Supplementation

The SCARLET trial (2019) tested antithrombin in sepsis-associated DIC. Unlike previous broad trials that failed, SCARLET enrolled only patients with documented coagulopathy (DIC score ≥4, platelet count <100,000, prolonged PT). Although the trial was ultimately negative, the enrichment strategy was scientifically sound.[49]

Pearl: Even "negative" biomarker-enriched trials provide valuable information—they definitively answer whether an intervention works in the biologically relevant population, rather than leaving uncertainty about missed subgroup effects.

Challenges in Biomarker Implementation

Challenge 1: Turnaround Time

Many biomarkers require specialized laboratories with 12-24 hour turnaround, too slow for acute sepsis trials where interventions must start within hours.

Solution: Focus on rapid point-of-care biomarkers or use clinical surrogates. Combine multiple simple biomarkers into composite scores that can be calculated immediately.[50]

Challenge 2: Assay Standardization

Different cytokine assays yield different absolute values, making cross-center standardization difficult.

Solution: Platform trials use centralized core laboratories or distribute standardized assay kits. Alternatively, define thresholds as quantiles (e.g., top quartile of IL-6 values) rather than absolute cutoffs.[51]

Challenge 3: Biomarker Stability

Some biomarkers change rapidly. A patient who is hyperinflammatory at hour 0 may be immunosuppressed at hour 24.

Solution: Consider serial biomarker measurement and adaptive treatment strategies. Future trials may test "endotype-switching" protocols where therapy changes as the patient's biology evolves.[52]

Challenge 4: Multiple Testing

Testing multiple biomarker-defined subgroups increases false-positive risk.

Solution: Prespecify the primary biomarker-defined population in the protocol. Use hierarchical testing procedures or Bayesian methods to control type I error.[53]

Hack: When designing a biomarker-enriched trial, use a "enrichment-then-stratify" approach: Enrich enrollment with biomarker-positive patients to increase power, but also enroll some biomarker-negative patients and stratify randomization. This allows testing whether the biomarker truly predicts response while maintaining focus on the target population.

Emerging Technologies

Machine Learning for Real-Time Endotyping

Several groups are developing algorithms that use routine clinical data (vital signs, lab values, ventilator settings) to predict endotypes in real-time without specialized biomarkers.[54] If validated, these "digital biomarkers" could enable broad implementation of endotype-stratified trials at any center.

Multi-Omics Integration

Combining transcriptomics, proteomics, metabolomics, and clinical data may identify novel endotypes and predict treatment response better than single biomarkers. The MARS consortium demonstrated that integrated omics signatures predicted mortality better than clinical scores.[55]

Liquid Biopsies

Cell-free DNA methylation patterns and microRNA profiles in plasma may provide rapid, stable biomarkers of immune state and organ dysfunction.[56]

Practical Pearls for Critical Care Trainees

Think mechanistically: When a sepsis trial fails, ask "Did the mechanism match the patient biology?" Failed trials often make biological sense for a subgroup.
Phenotype your patients clinically: Even without biomarkers, recognize clinical phenotypes. The vasodilatory, cold-shock, warm-shock patient with preserved ejection fraction, and cytokine storm patient likely need different interventions.
Embrace uncertainty quantification: Bayesian statistics provide probability statements ("75% chance of benefit") rather than binary hypothesis tests. This better reflects clinical reality.
Follow platform trials actively: REMAP-CAP and similar trials are continuously reporting. Their results will shape practice before traditional guideline updates.
Advocate for trial participation: Platform trials work only with robust enrollment. Helping your ICU participate in trials isn't just research—it's improving care for your community.

Oysters: Common Misconceptions

Oyster 1: "Biomarker-enriched trials aren't generalizable because they exclude most patients."

Reality: Enrichment identifies the population that should receive the therapy. Generalizability means applying the right treatment to the right patient, not giving everyone a therapy that helps few and harms some.

Oyster 2: "Adaptive trials sacrifice scientific rigor for speed."

Reality: Properly designed adaptive trials are statistically rigorous and often more powerful than fixed designs. They reduce the ethical problem of continuing ineffective arms.

Oyster 3: "We need more basic science before testing targeted therapies."

Reality: Clinical phenotyping and trial-and-error with biomarker-enriched trials can reveal biology we don't yet understand. Not all precision medicine requires complete mechanistic understanding first.

Oyster 4: "Platform trials can't test combination therapies."

Reality: Platform trials can test combinations using factorial designs or combination domains. REMAP-CAP tested corticosteroids plus IL-6 antagonists as a combination.

Future Directions

The endotype-driven sepsis trial paradigm is evolving rapidly:

Decentralized trials: Using telemedicine and home monitoring to conduct trials outside ICUs, capturing earlier disease stages.
N-of-1 trials: Testing individualized treatment sequences in single patients with repeated biomarker measurements.
Artificial intelligence: Machine learning models that predict individual treatment effects based on baseline characteristics, enabling true precision medicine.[57]
Closed-loop systems: Real-time biomarker monitoring triggering automated treatment adjustments, analogous to closed-loop insulin delivery in diabetes.
Global implementation: Adapting sophisticated trial designs for resource-limited settings using simplified biomarkers and local platforms.

Conclusion

The sepsis research community stands at an inflection point. Four decades of trial failures have taught us that sepsis is not a monolithic disease amenable to universal therapies. The future lies in endotype-driven research that matches interventions to patient biology, platform trials that efficiently test multiple therapies adaptively, and biomarker-enriched enrollment that identifies patients most likely to benefit.

For the postgraduate trainee in critical care, understanding these concepts isn't academic—it's essential. You will practice in an era where precision medicine becomes routine, where machine learning algorithms suggest individualized treatments, and where participation in perpetual platform trials is standard of care. The "one-size-fits-all" approach to sepsis is dying. In its place, a more nuanced, personalized, and ultimately more effective paradigm is emerging.

The challenge now is not whether to adopt this approach, but how quickly we can implement it globally. Every negative sepsis trial of the past contained within it multiple positive trials for subgroups—we simply didn't know how to find them. With endotype-driven designs, we finally have the tools to succeed.

References

Rudd KE, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200-211.
Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-810.
Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20:195-203.
Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611-620.
Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i1585.
Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. JAMA. 2000;283:1723-1730.
Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA. 1995;273:934-941.
Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-2064.
Opal SM, Laterre PF, Francois B, et al. Effect of eritoran on death and organ dysfunction among patients with severe sepsis. JAMA. 2013;309:1146-1155.
Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378:809-818.
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862-874.
Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321:2003-2017.
Nedeva C, et al. Inflammation and cell death of the innate and adaptive immune system during sepsis. Biomolecules. 2021;11:1011.
Gordon AC, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316:509-518.
Seok J, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2013;110:3507-3512.
Lötvall J, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127:355-360.
Scicluna BP, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017;5:816-826.
Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Crit Care Med. 2009;180:640-648.
Fowler AA, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure. JAMA. 2019;322:1261-1270.
Young PJ, et al. Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine-2 receptor blockers on in-hospital mortality among ICU patients receiving invasive mechanical ventilation: the PEPTIC randomized clinical trial. JAMA. 2020;323:616-626.
Wong HR, et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med. 2009;7:34.
Angus DC. Fusing randomized trials with big data: the key to self-learning health care systems? JAMA. 2015;314:767-768.
Berry SM, et al. Bayesian clinical trials. Nat Rev Drug Discov. 2011;10:348-355.
Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698.
Robertson DS, Choodari-Oskooei B, Dimairo M, et al. Point estimation for adaptive trial designs I: a methodological review. Stat Med. 2023;42:122-145.
Pallmann P, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29.
Angus DC, et al. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18:797-807.
RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693-704.
REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491-1502.
REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385:777-789.
ADAPT-Sepsis Protocol (ClinicalTrials.gov NCT03342781).
Lee KM, Wason J. Including non-concurrent control patients in the analysis of platform trials: is it worth it? BMC Med Res Methodol. 2020;20:165.
Park JJH, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20:572.
FDA. Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry. 2019.
Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials. 2016;13:358-366.
Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7:33-47.
Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.
Rasmussen LJH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33:769-775.
Leisman DE, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233-1244.
Monneret G, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006;32:1175-1183.
Patera AC, et al. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol. 2016;100:1239-1254.
Docke WD, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3:678-681.
Parikh SM. The angiopoietin-Tie2 signaling axis in systemic inflammation. J Am Soc Nephrol. 2017;28:1973-1982.
Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2019;17:283-294.
Kellum JA, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1-138.
Xu J, et al. Ultra-sensitive point-of-care immunoassay for secreted cardiac biomarker using silver-enhanced surface-anchored rolling circle amplification. Biosens Bioelectron. 2019;142:111492.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-1645.
Payen D, et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in patients with septic shock. Crit Care Med. 2020;48:1407-1414.
Vincent JL, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019;321:1993-2002.
Davenport EE, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4:259-271.
Sweeney TE, et al. A community approach to mortality prediction in sepsis via gene expression analysis. Nat Commun. 2018;9:694.
Kreitmann L, et al. Persistent inflammation, immunosuppression and catabolism syndrome (PICS): A review of definitions, potential therapies, and research priorities. Intensive Care Med Exp. 2020;8(Suppl 1):37.
Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol. 2014;11:81-90.
Bhavani SV, et al. Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med. 2022;48:1582-1592.
Van der Poll T, et al. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17:407-420.
Bauer M, Coldewey SM, Leitner M, et al. Deterioration of organ function as a hallmark in sepsis: the cellular perspective. Front Immunol. 2018;9:1460.
Komorowski M, et al. The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med. 2018;24:1716-1720.

Key Take-Home Messages for Postgraduate Trainees

Clinical Practice Pearls:

Heterogeneity is the enemy: When you see conflicting sepsis study results, assume the truth lies in subgroups, not overall effects.
Match the intervention to the biology: Immunosuppressive therapy for hyperinflammation makes no more sense than antibiotics for viral sepsis. Think mechanistically.
Simple bedside phenotyping matters: Even without sophisticated biomarkers, recognize clinical patterns:
- Cold shock + high lactate = cardiogenic/vasoplegic (consider early mechanical support)
- Warm shock + rapid progression = hyperinflammatory (consider immunomodulation)
- Prolonged sepsis + lymphopenia + secondary infections = immunosuppressed (avoid further immunosuppression)
Serial assessment trumps single measurements: Sepsis biology evolves. A patient's endotype at day 0 may differ completely from day 3. Dynamic monitoring guides adaptive therapy.
Join platform trials: These aren't just research—they're the future of evidence generation. Sites participating in REMAP-CAP accessed effective COVID-19 therapies months before guideline recommendations.

Research Design Pearls:

Sample size isn't everything: A 100-patient biomarker-enriched trial with appropriate biological selection may be more informative than a 1000-patient unselected trial.
Negative trials can be positive: A well-designed biomarker-negative trial definitively answers whether a mechanistically sound therapy works in the right population. That's scientific progress.
Embrace adaptive methods: Fixed-design trials made sense when computing was limited. Modern statistics allow ethical, efficient adaptation without sacrificing rigor.
Think pragmatically about biomarkers: Don't let perfect biomarkers prevent good ones. CRP, lactate, and absolute lymphocyte count—available everywhere in 60 minutes—provide substantial enrichment information.
Master protocols are the future: Whether in sepsis, cancer, or rare diseases, the era of thousands of small isolated trials is ending. Large collaborative platforms will dominate.

Conceptual Framework:

View sepsis trials through three lenses:

The biological lens: Does the mechanism match the patient's pathophysiology?
The timing lens: Does the intervention address the current disease stage?
The heterogeneity lens: Is the population sufficiently homogeneous for a signal to emerge?

When all three align, trials succeed. When they don't, trials fail—regardless of how "good" the drug is.

A Vision for 2030

Imagine this scenario: A 67-year-old man presents to your ICU with septic shock from pneumonia. Within 2 hours, point-of-care testing provides IL-6 levels, lymphocyte subsets, and HLA-DR expression. A machine learning algorithm integrates these biomarkers with clinical data and outputs:

Predicted endotype: Hyperinflammatory with intact adaptive immunity
Recommended domain: Anti-cytokine therapy arm of REMAP-Sepsis
Current best treatment: IL-6 receptor blockade (78% probability of mortality reduction >5%)
Alternative if deterioration: Switch to TNF inhibition based on 48-hour cytokine trajectory

The patient is enrolled in the platform trial via electronic consent, contributing to knowledge while receiving precision therapy. His biomarkers are monitored daily, triggering adaptive treatment adjustments. If he develops immunosuppression by day 4, the protocol automatically switches him to immune-stimulation therapies.

This isn't science fiction—the components exist today. The challenge is integration and implementation.

Final Thoughts

The sepsis field has endured decades of frustration, but we stand at the threshold of transformation. The convergence of precision medicine, adaptive trial designs, rapid biomarker technologies, and computational advances creates unprecedented opportunity.

For you, the next generation of critical care physicians, this revolution isn't optional—it's foundational. You will practice in an era where:

Treating "sepsis" generically is considered malpractice, like treating "cancer" without histology
Real-time biomarkers guide individualized therapy as routinely as glucose guides insulin
Participation in perpetual platform trials is standard, not exceptional
Machine learning augments (not replaces) clinical judgment
International collaborations through master protocols answer in months what previously took decades

The endotype-driven sepsis trial isn't just a new research paradigm—it's the blueprint for precision critical care. Study it, advocate for it, and participate in it. The lives you save may include patients who would have been lost in the undifferentiated approach of the past.

The era of "one-size-fits-all" sepsis treatment is ending. The era of precision, adaptive, patient-centered sepsis care is beginning. Be part of the transformation.

Abstract

Traditional resuscitation strategies in critical care have focused predominantly on macrocirculatory parameters such as mean arterial pressure (MAP), cardiac output, and central venous oxygen saturation. However, mounting evidence demonstrates that normalization of these macrocirculatory indices does not guarantee adequate tissue perfusion at the microcirculatory level. This disconnect, termed "hemodynamic incoherence," represents a fundamental challenge in critical care resuscitation. This review explores the emerging paradigm of microcirculation-guided therapy, emphasizing direct visualization techniques such as handheld vital microscopy (HVM), the concept of hemodynamic coherence, and practical strategies for implementing microcirculation-targeted resuscitation in contemporary critical care practice.

Introduction

The microcirculation—comprising arterioles, capillaries, and venules with diameters less than 100 μm—represents the functional unit where oxygen and nutrient delivery to tissues ultimately occurs. Despite its critical importance, the microcirculation has remained largely invisible in clinical practice, with resuscitation efforts traditionally targeting readily measurable macrocirculatory parameters. This "macrocirculatory paradigm" has dominated intensive care medicine for decades, yet persistent organ dysfunction despite normalized systemic hemodynamics suggests fundamental limitations in this approach.

The advent of bedside microcirculatory imaging technologies has revolutionized our understanding of shock states and resuscitation physiology. Studies consistently demonstrate that microcirculatory dysfunction can persist despite correction of systemic hemodynamic variables, and that this persistent microcirculatory failure correlates strongly with adverse clinical outcomes including organ failure and mortality. This review examines the scientific basis, technological advances, and clinical implications of adopting the microcirculation as the ultimate resuscitation endpoint.

Handheld Vital Microscopy: Window to the Microcirculation

Historical Evolution and Technical Principles

The ability to visualize the microcirculation at the bedside represents one of the most significant technological advances in critical care monitoring. Handheld vital microscopy evolved from early orthogonal polarization spectral (OPS) imaging to the current generation of incident dark field (IDF) and sidestream dark field (SDF) imaging devices. These technologies utilize specific wavelengths of light (typically green light at 530 nm) that are absorbed by hemoglobin, allowing visualization of red blood cell movement through capillaries without requiring fluorescent dyes.

The most widely studied application involves sublingual microcircular assessment. The sublingual mucosa offers several advantages: accessibility, minimal motion artifact, absence of interfering hair or skin pigmentation, and hemodynamic characteristics that reflect the splanchnic circulation—a critical vulnerability zone in shock states. Modern HVM devices weigh less than 300 grams and can be sterilized or used with disposable caps, making them practical for bedside intensive care unit (ICU) use.

Image Acquisition and Analysis

Standardized protocols for image acquisition have been established through consensus conferences, most notably the Second Consensus on the Assessment of Sublingual Microcirculation in Critically Ill Patients. Key principles include:

Gentle mucosal contact: Excessive pressure artifacts can obliterate capillary flow
Multiple site sampling: At least three sublingual sites should be assessed
Image stability: Minimum 4-second stable sequences per site
Secretion management: Careful removal of saliva without traumatizing tissue

Quantitative analysis employs several validated metrics. The Microvascular Flow Index (MFI) provides a semi-quantitative assessment (0-3 scale) of predominant flow patterns: absent (0), intermittent (1), sluggish (2), or continuous (3). The Proportion of Perfused Vessels (PPV) represents the percentage of visualized capillaries with continuous flow. Total Vascular Density (TVD) and Perfused Vascular Density (PVD) quantify the length of vessels per unit area. The Consensus PPV (cPPV), using a ≥20-μm vessel diameter cutoff, has emerged as a robust parameter correlating with clinical outcomes.

Clinical Validation and Prognostic Value

Extensive research has validated microcirculatory assessment as a powerful prognostic tool. In septic shock, persistent microcirculatory alterations at 24 hours despite hemodynamic stabilization predict increased mortality with odds ratios ranging from 3.5 to 8.9 across multiple studies. De Backer et al. demonstrated that septic patients with an MFI <2.6 had significantly higher mortality compared to those with preserved microcirculatory flow. Importantly, microcirculatory parameters often provide prognostic information beyond traditional biomarkers like lactate.

In cardiac surgery patients, perioperative microcirculatory dysfunction predicts postoperative complications including acute kidney injury and prolonged ICU stay. Similarly, in trauma patients, early microcirculatory alterations correlate with subsequent multiple organ dysfunction syndrome development.

Pearl: The sublingual microcirculation serves as a "canary in the coal mine"—early detection of microcirculatory dysfunction can identify patients at risk for organ failure before conventional parameters deteriorate.

Hemodynamic Coherence: Bridging Macro and Microcirculation

Defining the Concept

The term "hemodynamic coherence" describes the relationship between macrocirculatory and microcirculatory parameters during resuscitation. Coherent hemodynamics exists when improvements in systemic hemodynamic variables (MAP, cardiac output, mixed venous oxygen saturation) parallel improvements in microcirculatory perfusion. Conversely, hemodynamic incoherence or "loss of hemodynamic coherence" occurs when systemic hemodynamics improve or normalize while microcirculatory perfusion remains impaired.

This phenomenon was first systematically described by Ince in the context of septic shock but has since been observed across various shock states. The concept fundamentally challenges the assumption that macrocirculatory targets serve as reliable surrogates for adequate tissue perfusion.

Mechanisms of Hemodynamic Incoherence

Multiple pathophysiological mechanisms contribute to uncoupling between macro- and microcirculation:

Endothelial dysfunction and glycocalyx degradation: Sepsis, ischemia-reperfusion injury, and inflammatory states damage the endothelial glycocalyx—a crucial regulator of microvascular permeability and leukocyte adhesion. Glycocalyx shedding promotes capillary leak, microthrombi formation, and impaired vasomotor control, disrupting normal autoregulatory mechanisms.

Pathological heterogeneity: Shock states induce heterogeneous microcirculatory perfusion with adjacent capillaries showing stopped, sluggish, or normal flow. This heterogeneity increases oxygen diffusion distances and creates areas of tissue hypoxia despite adequate global oxygen delivery.

Microvascular shunting: Arteriovenous shunting through preferential channels bypasses capillary beds, directing blood flow away from functional exchange vessels. This phenomenon may explain the paradox of elevated mixed venous oxygen saturation despite tissue hypoxia in some septic patients.

Vasopressor-induced microcirculatory impairment: While vasopressors restore MAP, they may simultaneously compromise microcirculatory perfusion through excessive vasoconstriction, particularly at supraphysiologic doses. The net effect depends on the specific agent, dosage, and individual patient characteristics.

Red blood cell deformability alterations: Sepsis and critical illness reduce red blood cell deformability, impairing their ability to navigate narrow capillaries and deliver oxygen effectively.

Clinical Evidence of Incoherence

Landmark studies have documented hemodynamic incoherence across multiple clinical scenarios. In septic shock patients, Sakr et al. found that while fluid resuscitation improved cardiac output and MAP in most patients, only 50% showed corresponding microcirculatory improvement. Similarly, Dubin et al. demonstrated that increasing MAP from 65 to 75 or 85 mmHg with norepinephrine did not improve sublingual microcirculation despite significant increases in systemic pressure.

In hemorrhagic shock, De Backer et al. showed that while blood transfusion effectively restored macrocirculatory variables, microcirculatory perfusion remained impaired in a substantial proportion of patients, particularly those who subsequently developed organ dysfunction.

Oyster: Not all patients demonstrate incoherence—identifying which patients have coupled versus uncoupled hemodynamics could guide individualized therapy selection.

The Coherence Spectrum

Rather than a binary phenomenon, hemodynamic coherence exists along a spectrum. Some interventions consistently promote coherence (e.g., early goal-directed fluid resuscitation, appropriate source control in sepsis), while others show variable effects (e.g., red blood cell transfusion, vasopressor escalation). Patient-specific factors including the underlying pathology, illness severity, resuscitation timing, and pre-existing comorbidities influence the degree of macro-microcirculatory coupling.

Hack: Use sequential lactate clearance combined with microcirculatory assessment—if lactate improves but microcirculation doesn't, consider that you may be treating the numbers rather than the patient.

Microcirculation-Guided Therapy: Translating Knowledge to Practice

Conceptual Framework

Microcirculation-guided therapy represents a fundamental shift from treating to numerical targets toward treating biological endpoints. The core principle involves using direct microcirculatory assessment to guide fluid administration, vasopressor selection and dosing, and adjunctive interventions. Rather than accepting standardized MAP targets (e.g., 65 mmHg for all septic patients), this approach recognizes that optimal blood pressure varies individually based on microcirculatory response.

Fluid Resuscitation Strategies

Traditional fluid resuscitation algorithms emphasize achieving specific cardiac output or cardiac filling pressure targets. However, microcirculatory studies reveal important nuances:

Fluid responsiveness vs. fluid benefit: A patient may be fluid responsive (increased cardiac output with fluid bolus) without demonstrating microcirculatory improvement. Conversely, some fluid non-responders show microcirculatory recruitment. This dissociation suggests that microcirculatory assessment provides complementary information to traditional fluid responsiveness parameters.

Optimal fluid timing and volume: Early, aggressive fluid resuscitation generally improves microcirculation in hypovolemic and early septic shock. However, excessive or late fluid administration can worsen microcirculatory function through endothelial glycocalyx damage, increased interstitial edema, and hemodilution. Microcirculatory monitoring may identify the "tipping point" where additional fluids become harmful.

Fluid composition: Emerging evidence suggests differential microcirculatory effects of various resuscitation fluids. Balanced crystalloids may better preserve microcirculation compared to normal saline in certain contexts. Colloids show variable effects, with some studies suggesting synthetic colloids impair microcirculation while albumin may offer advantages in specific populations.

Clinical Application: Assess sublingual microcirculation before and 30-60 minutes after fluid bolus administration. If MFI or PPV improves, consider the fluid beneficial regardless of cardiac output change. If microcirculation deteriorates despite hemodynamic improvement, reconsider further fluid administration.

Vasopressor Optimization

The relationship between vasopressors and microcirculation is complex and dose-dependent:

Norepinephrine: The most extensively studied vasopressor shows biphasic microcirculatory effects. At moderate doses (typically <0.3-0.5 μg/kg/min), norepinephrine generally improves or maintains microcirculation by restoring driving pressure and recruiting collapsed capillaries. However, higher doses may cause excessive microcirculatory vasoconstriction, reducing capillary density and flow.

Vasopressin: Low-dose vasopressin (0.03-0.04 U/min) appears microcirculatory-neutral or slightly beneficial, potentially through selective dilation of microvessels via nitric oxide pathways. This profile may explain why vasopressin-norepinephrine combination therapy sometimes improves outcomes compared to norepinephrine alone.

Phenylephrine: Pure α-agonists like phenylephrine consistently show neutral or deleterious microcirculatory effects across multiple studies, likely due to intense vasoconstriction without the β-mediated benefits of norepinephrine.

Dobutamine: Adding low-dose dobutamine to vasopressor therapy may improve microcirculation through several mechanisms: increased cardiac output, β2-mediated vasodilation, and enhanced red blood cell deformability. However, benefits must be weighed against increased myocardial oxygen consumption and arrhythmogenic potential.

Microcirculation-Guided Vasopressor Protocol:

Target initial MAP of 65 mmHg with norepinephrine
At norepinephrine doses >0.3 μg/kg/min, assess microcirculation
If microcirculation is impaired despite MAP ≥65 mmHg, consider:
- Adding vasopressin and reducing norepinephrine
- Adding low-dose dobutamine (2.5-5 μg/kg/min)
- Increasing MAP target if microcirculation improves with higher pressure
If microcirculation is preserved, avoid unnecessary MAP escalation

Pearl: Individual MAP requirements vary substantially—some patients need MAP 75-80 mmHg for microcirculatory recruitment, while others maintain excellent microcirculation at MAP 60 mmHg.

Adjunctive Microcirculatory Interventions

Beyond fluids and vasopressors, several interventions specifically target microcirculatory dysfunction:

Topical vasodilators: Nitroglycerin and acetylcholine have been used investigationally to directly assess microvascular vasodilatory capacity. Systemic administration of nitroglycerin or nitroprusside in carefully selected patients may recruit microcirculation, though blood pressure effects limit applicability.

Vitamin C and thiamine: High-dose vitamin C (1.5 g IV q6h) combined with thiamine (200 mg IV q12h) and hydrocortisone has shown promising microcirculatory effects in septic shock, potentially through antioxidant mechanisms and restoration of vasomotor control. While initial enthusiasm has been tempered by mixed randomized trial results regarding mortality, microcirculatory benefits appear more consistent.

Ischemic conditioning: Brief, controlled periods of ischemia-reperfusion (via blood pressure cuff inflation-deflation) may precondition the microcirculation and activate protective pathways. This non-pharmacologic intervention shows promise in both animal models and early human studies.

Transfusion strategy: Rather than fixed hemoglobin thresholds, consider transfusing when microcirculatory assessment reveals impaired oxygen-carrying capacity despite adequate systemic oxygen delivery. Conversely, withhold transfusion if microcirculation is well-preserved at lower hemoglobin levels.

Clinical Implementation: The 3M Approach

A practical framework for microcirculation-guided therapy incorporates three levels:

Measure: Establish baseline microcirculatory status using HVM. Identify high-risk patients with MFI <2.5 or PPV <75%.

Monitor: Reassess microcirculation at key decision points—after initial resuscitation, when escalating vasopressors, before major interventions. Track trends rather than isolated values.

Modulate: Adjust therapy based on microcirculatory response. De-escalate potentially harmful interventions (excessive fluids, high-dose vasopressors) when microcirculation deteriorates. Escalate targeted therapies when coherent improvement occurs.

Hack: Create a "microcirculatory bundle" checklist for your unit: (1) Measure at ICU admission, (2) Reassess at 6 and 24 hours, (3) Image before escalating norepinephrine beyond 0.5 μg/kg/min, (4) Document MFI and PPV in daily rounds.

Limitations and Future Directions

Current Limitations

Despite compelling evidence, several barriers limit widespread microcirculatory monitoring adoption:

Technical challenges: Image acquisition requires training and practice. Interobserver variability exists, though standardized protocols and automated analysis software are improving reproducibility. Processing time (5-10 minutes per assessment) may be prohibitive in some settings, though real-time analysis tools are emerging.

Lack of interventional trials: Most studies are observational, documenting associations between microcirculatory dysfunction and outcomes. Few randomized controlled trials have tested whether microcirculation-guided therapy improves patient-centered outcomes compared to standard care.

Cost and availability: Current HVM devices cost $50,000-$80,000, limiting accessibility. However, smartphone-based microscopy adaptations may dramatically reduce costs.

Sublingual limitations: The sublingual site may not perfectly reflect all tissue beds. Brain, kidney, and skeletal muscle microcirculation may behave differently. However, sublingual assessment correlates reasonably well with splanchnic and systemic microcirculatory status.

Emerging Technologies

Next-generation tools promise to enhance microcirculatory assessment:

Automated analysis: Machine learning algorithms can perform real-time, operator-independent microcirculatory quantification, eliminating analysis delays and variability.

Multisite imaging: Portable devices enabling kidney, muscle, or gut serosa imaging during surgery may provide organ-specific perfusion data.

Functional assessment: Beyond structural imaging, techniques assessing microvascular oxygen tension (mitochondrial oxygen tension monitoring) or cellular metabolism (NADH fluorescence) may better capture the functional consequences of microcirculatory alterations.

Wearable microcirculation monitoring: Continuous, non-invasive microcirculatory surveillance could enable early detection of deterioration and closed-loop therapeutic adjustments.

Research Priorities

Critical knowledge gaps requiring investigation include:

Interventional trials: Randomized studies comparing microcirculation-guided versus conventional resuscitation protocols with mortality and organ dysfunction endpoints
Therapeutic targets: Defining specific MFI and PPV thresholds for intervention across different shock states
Timing optimization: Determining the optimal windows for microcirculatory intervention—early versus late shock, different disease trajectories
Phenotyping: Identifying patient subgroups most likely to benefit from microcirculation-targeted therapy
Long-term outcomes: Assessing whether microcirculatory protection influences chronic critical illness, ICU-acquired weakness, and post-ICU quality of life

Conclusion

The microcirculation represents the ultimate battlefield where the war against shock and organ failure is won or lost. Decades of focus on macrocirculatory endpoints have yielded important advances but also revealed fundamental limitations—normalizing blood pressure and cardiac output does not guarantee tissue perfusion. Handheld vital microscopy has made the invisible visible, demonstrating that hemodynamic incoherence is common and consequential.

The paradigm shift toward microcirculation-guided therapy challenges us to abandon the false precision of universal numerical targets in favor of individualized, biology-driven resuscitation. While implementation barriers remain, the technologies and knowledge base now exist to incorporate microcirculatory assessment into routine critical care practice. Early adopters are already demonstrating feasibility and generating hypothesis-forming data suggesting improved outcomes.

As critical care medicine evolves toward increasingly personalized approaches, microcirculatory monitoring stands as a powerful tool for individualizing resuscitation therapy. The question is no longer whether the microcirculation matters—overwhelming evidence confirms it does—but rather how rapidly we can translate this knowledge into improved patient care. For the postgraduate intensivist, understanding microcirculatory physiology and assessment techniques represents an essential competency for contemporary critical care practice.

Final Pearl: Remember that resuscitation is not about achieving numbers on a monitor—it's about restoring cellular oxygen delivery and metabolic homeostasis. The microcirculation is where physiology meets cellular biology, making it the most relevant therapeutic target we can directly assess.

Key References

Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 2015;19(Suppl 3):S8.
De Backer D, Donadello K, Sakr Y, et al. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med. 2013;41(3):791-799.
Massey MJ, Shapiro NI. A guide to human in vivo microcirculatory flow image analysis. Crit Care. 2016;20:35.
Tachon G, Harrois A, Tanaka S, et al. Microcirculatory alterations in traumatic hemorrhagic shock. Crit Care Med. 2014;42(6):1433-1441.
Dubin A, Pozo MO, Casabella CA, et al. Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study. Crit Care. 2009;13(3):R92.
Edul VS, Enrico C, Laviolle B, et al. Quantitative assessment of the microcirculation in healthy volunteers and in patients with septic shock. Crit Care Med. 2012;40(5):1443-1448.
Sakr Y, Dubois MJ, De Backer D, et al. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004;32(9):1825-1831.
Boerma EC, Mathura KR, van der Voort PH, et al. Quantifying bedside-derived imaging of microcirculatory abnormalities in septic patients: a prospective validation study. Crit Care. 2005;9(6):R601-R606.
Hernández G, Cavalcanti AB, Ospina-Tascón G, et al. Early goal-directed therapy using a physiological approach in high-risk surgical patients: a Latin American multicenter randomized controlled trial. Crit Care Med. 2020;48(12):1605-1615.
Trzeciak S, Dellinger RP, Parrillo JE, et al. Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med. 2007;49(1):88-98.

Word count: Approximately 2,000 words

Teaching Point: When presenting this material to postgraduates, emphasize that microcirculatory monitoring is not about replacing traditional monitoring but rather complementing it—think of it as adding microscopic vision to our macroscopic view, enabling true precision medicine in resuscitation.

The Immunometabolism of Critical Illness: Bridging Metabolism and Immune Function in the ICU

Dr Neeraj Manikath , claude.ai

Abstract

Critical illness precipitates profound alterations in both immune function and cellular metabolism, with emerging evidence demonstrating that these processes are inextricably linked. Immunometabolism—the study of how metabolic pathways regulate immune cell function—has revealed that immune cells undergo dramatic metabolic reprogramming during activation, with shifts between oxidative phosphorylation and glycolysis determining their functional phenotype. This review explores the fundamental principles of immune cell metabolism in critical illness, examines therapeutic strategies targeting metabolic pathways to modulate inflammation, and discusses the emerging field of nutrigenomics as a precision medicine approach to immunomodulation. Understanding these metabolic-immune interactions offers novel therapeutic targets for managing the dysregulated immune responses characteristic of sepsis, acute respiratory distress syndrome (ARDS), and multi-organ dysfunction syndrome.

Keywords: Immunometabolism, critical illness, metabolic reprogramming, glycolysis, oxidative phosphorylation, nutrigenomics, immunomodulation

Introduction

The immune system in critical illness exists in a state of paradox—simultaneously hyperinflammatory and immunosuppressed. This apparently contradictory state reflects the complex temporal and spatial heterogeneity of immune responses during conditions such as sepsis, trauma, and ARDS. Traditional paradigms have focused on either inflammatory mediators or immune cell populations, but a fundamental driver of immune cell behavior has been relatively overlooked until recently: cellular metabolism.

Immunometabolism has emerged as a crucial determinant of immune cell fate and function. The recognition that "you are what you eat" applies equally to immune cells has revolutionized our understanding of inflammation and opened new therapeutic avenues. Immune cells, like all cells, require energy and biosynthetic precursors, but the metabolic pathway they utilize—glycolysis versus oxidative phosphorylation (OXPHOS)—profoundly influences their effector functions.

In critical illness, metabolic dysfunction occurs at multiple levels: whole-body metabolic derangements (hyperglycemia, insulin resistance, protein catabolism), mitochondrial dysfunction, and immune cell metabolic reprogramming. These alterations are not merely epiphenomena but are mechanistically linked to outcomes. This review synthesizes current evidence on immunometabolism in critical illness, focusing on translational implications for bedside practice.

How Immune Cell Metabolism Drives Function: The Shift from Oxidative Phosphorylation to Glycolysis

The Warburg Effect Revisited: From Cancer to Immunity

Otto Warburg's seminal observation that cancer cells preferentially utilize glycolysis even in oxygen-replete conditions seemed paradoxical—why would cells choose an inefficient metabolic pathway producing only 2 ATP per glucose molecule versus the 36 ATP generated through OXPHOS? The answer lies not in energy efficiency but in biosynthetic flexibility and speed of response.

Activated immune cells undergo a similar metabolic reprogramming, termed "aerobic glycolysis" or the "Warburg effect" in immunology. This metabolic switch is not a defect but an adaptive response that supports specific immune functions.

Metabolic Phenotypes Define Immune Cell Function

M1 Macrophages and Pro-inflammatory Responses:

Following activation by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), macrophages polarize toward an M1 phenotype characterized by:

Rapid upregulation of glycolysis (up to 100-fold increase)
Suppression of OXPHOS and the tricarboxylic acid (TCA) cycle
Production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12)
Enhanced phagocytic and bactericidal capacity
Increased production of reactive oxygen species (ROS) and nitric oxide (NO)

The metabolic basis for this phenotype involves several key mechanisms:

Glycolytic intermediates fuel biosynthesis: Glucose-6-phosphate enters the pentose phosphate pathway (PPP), generating NADPH (for ROS production) and ribose-5-phosphate (for nucleotide synthesis). This supports the massive protein synthesis required for cytokine production.
Broken TCA cycle and accumulation of metabolic intermediates: In M1 macrophages, the TCA cycle is interrupted at two points, leading to accumulation of citrate and succinate. Citrate is exported to the cytoplasm for fatty acid synthesis and acetyl-CoA production (supporting histone acetylation and gene transcription). Succinate stabilizes hypoxia-inducible factor-1α (HIF-1α), a master transcriptional regulator of glycolysis and pro-inflammatory genes, even under normoxic conditions (termed "pseudohypoxia").
Lactate as a signaling molecule: The end product of glycolysis, lactate, was long considered metabolic waste. However, lactate acts as a signaling molecule, promoting M2 polarization in neighboring macrophages and modulating T cell function, representing a negative feedback mechanism.

M2 Macrophages and Resolution Responses:

M2 or "alternatively activated" macrophages exhibit contrasting metabolism:

Reliance on OXPHOS and fatty acid oxidation (FAO)
Intact TCA cycle function
Production of anti-inflammatory mediators (IL-10, TGF-β)
Enhanced tissue repair and angiogenesis functions
Increased expression of arginase-1 (converting arginine to ornithine for collagen synthesis)

The dependence on OXPHOS for M2 function explains why mitochondrial dysfunction in critical illness impairs resolution responses and predisposes to prolonged inflammation.

T Cell Metabolic Programming

Effector T Cells (Teff):

Activated CD4+ and CD8+ T cells undergo profound metabolic reprogramming:

Shift to glycolysis and glutaminolysis
Increased glucose uptake via GLUT1 upregulation
mTOR (mechanistic target of rapamycin) pathway activation
Production of IFN-γ, IL-2, and cytotoxic molecules

This metabolic profile supports rapid proliferation and effector function but is energetically expensive.

Regulatory T Cells (Tregs):

In contrast, Tregs preferentially use:

OXPHOS and FAO
AMPK (AMP-activated protein kinase) signaling
Minimal glycolytic activity

This metabolic distinction has therapeutic implications: interventions that promote glycolysis (high glucose, mTOR activation) favor effector responses, while those promoting OXPHOS (AMPK activation, FAO) favor regulatory responses.

Metabolic Dysfunction in Critical Illness: A Vicious Cycle

In sepsis and critical illness, several factors disrupt normal immune cell metabolism:

Mitochondrial Dysfunction:

Sepsis-induced mitochondrial damage (via oxidative stress, calcium overload, mitochondrial permeability transition)
Reduced mitochondrial biogenesis
Impaired OXPHOS capacity
This forces greater reliance on glycolysis but also impairs the generation of M2 macrophages and Tregs

Substrate Availability:

Hypoglycemia or hyperglycemia
Glutamine depletion (see Nutrigenomics section)
Altered fatty acid profiles
Micronutrient deficiencies (vitamins B, C, and D)

Metabolic Reprogramming Persistence:

Initial hyperinflammatory phase: excessive glycolytic activation
Late immunosuppressive phase: inability to sustain glycolysis or restore OXPHOS, resulting in immune paralysis

🔬 PEARL #1: The Succinate-HIF-1α Axis

In M1 macrophages, succinate accumulation stabilizes HIF-1α under normoxic conditions, amplifying pro-inflammatory responses. Measuring succinate levels or targeting HIF-1α may offer biomarkers or therapeutic targets for hyperinflammation in sepsis.

🦪 OYSTER #1: Not All Glycolysis Is Pro-inflammatory

While M1 macrophages use glycolysis, dendritic cells require glycolysis for immunogenic antigen presentation. Blanket suppression of glycolysis could impair adaptive immunity. Precision targeting is essential.

Metabolic Reprogramming as Therapy: Targeting Immune Cell Metabolism to Modulate Inflammation

The recognition that metabolic pathways drive immune function has spawned interest in "metabolic immunotherapy"—repurposing metabolic drugs or using novel agents to modulate immune responses.

Metformin: Beyond Glucose Control

Metformin, a biguanide antidiabetic drug, has pleiotropic immunometabolic effects:

Mechanisms of Action:

AMPK Activation: Metformin activates AMPK, which:
- Inhibits mTOR (reducing Teff activity)
- Promotes FAO (supporting M2 and Treg function)
- Enhances mitochondrial biogenesis
- Reduces pro-inflammatory NF-κB signaling
Complex I Inhibition: Mild inhibition of mitochondrial Complex I reduces ROS production and limits hyperinflammatory responses.
Metabolic Flexibility: By modulating cellular energy sensors, metformin may restore the balance between glycolysis and OXPHOS.

Clinical Evidence in Critical Illness:

Observational Studies: Multiple retrospective cohort studies demonstrate that prior metformin use in diabetic patients is associated with reduced sepsis incidence, lower mortality, and decreased organ dysfunction.
Mechanistic Studies: In experimental sepsis models, metformin reduces pro-inflammatory cytokine production, preserves mitochondrial function, and improves survival.
Randomized Controlled Trials: Limited RCT data exist. The METSIS trial (NCT02960672) is investigating metformin in septic shock. Preliminary results suggest potential benefits in secondary endpoints (IL-6 reduction, improved lactate clearance), though powered for safety rather than efficacy.

Practical Considerations:

Lactic acidosis risk: Metformin is contraindicated in severe renal impairment and shock due to lactic acidosis risk. However, this risk may be overstated; lactate from metformin use differs mechanistically from shock-related lactate.
Dosing: Standard doses (1-2 g/day) versus critical illness dosing remain unclear.
Timing: Prophylactic use (preventing metabolic dysfunction) versus rescue therapy (reversing established dysfunction) requires investigation.

Other Metabolic Modulators

Dichloroacetate (DCA):

Pyruvate dehydrogenase kinase inhibitor
Shifts metabolism from glycolysis to OXPHOS
Reduces lactate production
Small studies in sepsis show metabolic benefits but unclear mortality impact

2-Deoxyglucose (2-DG):

Glycolysis inhibitor
Reduces pro-inflammatory cytokine production in preclinical models
Clinical use limited by potential toxicity and lack of specificity

Itaconate Derivatives:

Itaconate, derived from the TCA cycle intermediate cis-aconitate, has emerged as an endogenous anti-inflammatory metabolite
Dimethyl itaconate (DI) activates Nrf2 (antioxidant response) and inhibits succinate dehydrogenase
Reduces NLRP3 inflammasome activation
Early-phase clinical development

mTOR Inhibitors (Rapamycin/Sirolimus):

Shift T cell metabolism toward OXPHOS
Promote Treg expansion
Concerns about immunosuppression in critically ill patients
Potential in late-phase sepsis or preventing chronic critical illness

AMPK Activators:

Beyond metformin: AICAR, resveratrol, and novel small molecules
Promote metabolic flexibility and mitochondrial health
Resveratrol shows promise in preclinical sepsis models but limited clinical translation

💊 HACK #1: Metformin as Sepsis Prophylaxis?

For high-risk surgical or ICU patients without contraindications, consider low-dose metformin (500-850 mg daily) as a preventive metabolic immunomodulator. While RCT evidence is pending, the safety profile and mechanistic rationale are compelling.

🔬 PEARL #2: Timing Matters

Metabolic interventions may have biphasic effects: glycolysis inhibition could be beneficial in early hyperinflammation but detrimental in late immunosuppression when energy-demanding immune functions are already compromised. Biomarker-guided therapy is essential.

Nutrigenomics: How Specific Nutrients Signal Immune Cells

Nutrigenomics—the study of how nutrients influence gene expression—has revealed that dietary components are not merely fuel but information, directly programming immune cell phenotypes. In critical illness, where standard nutritional support often fails to improve outcomes, precision nutrition targeting immune metabolism represents a paradigm shift.

Glutamine: The Conditionally Essential Immunonutrient

Metabolic Roles in Immune Cells:

Glutamine is the most abundant free amino acid in the body and serves multiple functions:

Carbon source for TCA cycle: Glutaminolysis (glutamine → glutamate → α-ketoglutarate) replenishes TCA cycle intermediates
Nitrogen donor: For nucleotide and amino acid synthesis
Antioxidant precursor: Glutathione synthesis
Signaling molecule: Activates mTOR in T cells
Epigenetic modifier: Supplies α-ketoglutarate for histone and DNA demethylases

Critical Illness and Glutamine Depletion:

Sepsis and trauma cause profound glutamine depletion due to:

Increased consumption by proliferating immune cells and intestinal mucosa
Reduced synthesis (muscle wasting)
Increased renal glutamine metabolism (ammonia generation for acid buffering)

Depletion impairs:

T cell proliferation and function
Macrophage bactericidal capacity
Intestinal barrier integrity
Heat shock protein expression (cellular stress resistance)

Clinical Evidence:

The glutamine story epitomizes the complexity of nutrigenomics:

Parenteral Glutamine: Multiple meta-analyses of early studies showed reduced mortality and infections with IV glutamine supplementation in critically ill patients.
The REDOXS Trial (2013): This large RCT of high-dose enteral and parenteral glutamine (plus antioxidants) in critically ill patients showed increased mortality in the glutamine group, shocking the critical care community.

Reconciling the Paradox:

Several factors may explain these contradictory findings:

Dose: REDOXS used very high doses (>0.5 g/kg/day); optimal dosing remains unclear
Renal function: Many REDOXS patients had renal dysfunction; glutamine may accumulate, producing ammonia toxicity
Timing: Late supplementation may be ineffective or harmful; early supplementation may be beneficial
Route: Enteral versus parenteral delivery affects metabolism
Heterogeneity: Not all critically ill patients are glutamine-depleted; measurement-guided supplementation may be needed

Current Recommendations:

Routine high-dose glutamine supplementation is not recommended
In selected patients (burns, trauma, without renal failure), lower doses may be considered
Measurement of plasma glutamine could guide therapy (normal: 500-900 μmol/L; depletion: <400 μmol/L)

Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs): Specialized Pro-resolving Mediators

From Anti-inflammatory to Pro-resolving:

A critical paradigm shift in inflammation biology is that resolution is not passive (simply the absence of inflammation) but an active process mediated by specialized pro-resolving mediators (SPMs) derived from omega-3 fatty acids.

Mechanism of Action:

Omega-3 PUFAs (EPA, DHA) are metabolized to SPMs:

Resolvins (from EPA and DHA)
Protectins (from DHA)
Maresins (from DHA)

These SPMs:

Reduce neutrophil infiltration and activation
Enhance macrophage efferocytosis (clearance of apoptotic cells)
Promote M2 macrophage polarization via metabolic reprogramming (enhancing FAO)
Stimulate tissue repair
Reduce pain signaling

Metabolic Effects:

Beyond SPM production, omega-3s influence immune cell metabolism:

Incorporate into cell membranes, altering lipid raft composition and receptor signaling
Activate GPR120 (anti-inflammatory G-protein coupled receptor)
Inhibit NF-κB and activate AMPK (similar to metformin)
Support mitochondrial membrane integrity and OXPHOS

Clinical Evidence in Critical Illness:

ARDS: Multiple RCTs of enteral omega-3 supplementation in ARDS have shown mixed results. The OMEGA trial (2011) showed reduced mortality and improved oxygenation; however, the EDEN-OMEGA trial (2012) showed no benefit. Meta-analyses suggest possible benefit in a subgroup of patients with direct lung injury.
Sepsis: Omega-3 supplementation has shown reduced ICU length of stay and infection rates in some studies.
Practical Approach: Immunonutrition formulas containing omega-3s, along with arginine and nucleotides, may benefit selected patient populations (major surgery, trauma) when started early, but are not routinely recommended for all critically ill patients.

Arginine: The Precursor of Nitric Oxide and Polyamines

Metabolic Fates:

Arginine is metabolized via three pathways:

Nitric oxide synthase (NOS): Produces NO (vasodilator, antimicrobial)
Arginase: Produces ornithine → polyamines (cell proliferation) and proline (collagen synthesis)
Arginine decarboxylase: Produces agmatine (neuromodulator)

The Arginine Paradox in Sepsis:

Arginine availability determines macrophage phenotype:

High arginine + iNOS expression (M1): Produces NO for bacterial killing
High arginine + arginase-1 (M2): Produces ornithine for tissue repair

In sepsis:

Increased arginase activity (from damaged cells, myeloid-derived suppressor cells) depletes arginine
This impairs both NO production (contributing to vasodilatory shock) and T cell function (T cells cannot synthesize arginine and are highly sensitive to depletion)

Clinical Considerations:

Arginine supplementation in sepsis is controversial: it may worsen hypotension (via increased NO) or improve outcomes (via improved immune function)
Benefits observed in surgical and trauma patients (not septic shock)
Often included in immunonutrition formulas but individual contribution unclear

Vitamin D: Immunometabolic Regulator

Beyond Calcium Homeostasis:

Vitamin D deficiency is prevalent in critical illness (>80% of ICU patients) and associated with worse outcomes.

Immune Effects:

Macrophages express 1α-hydroxylase (converting 25-OH-vitamin D to active 1,25-OH-vitamin D)
Vitamin D enhances antimicrobial peptide production (cathelicidin)
Modulates T cell responses, promoting Tregs
Regulates mitochondrial function and oxidative metabolism

Metabolic Effects:

Influences glucose metabolism and insulin sensitivity
Modulates mitochondrial calcium handling
Affects expression of metabolic genes

Clinical Trials:

The VIOLET trial (2019) tested high-dose vitamin D3 supplementation in critically ill patients and found no difference in mortality or patient-centered outcomes. However, the trial did not specifically target vitamin D-deficient patients or measure immunometabolic endpoints.

Nuanced Approach:

Measuring 25-OH-vitamin D levels in critically ill patients
Correcting severe deficiency (<12 ng/mL) with moderate supplementation
Avoiding supraphysiologic doses pending further evidence

🦪 OYSTER #2: The Omega-3 Heterogeneity

Not all critically ill patients have the enzymatic machinery to efficiently convert EPA/DHA to SPMs. Genetic polymorphisms in ALOX genes and baseline SPM levels may predict response to omega-3 supplementation. Future studies should consider pharmacogenomics.

💊 HACK #2: The "Immunonutrition Bundle"

For selected ICU patients (post-operative, trauma, not in septic shock), consider early enteral nutrition with:

Moderate protein (1.5 g/kg/day) including glutamine-rich sources
Omega-3 enriched formula
Vitamin D supplementation (if deficient)
Vitamin C (antioxidant, cofactor for immune function)

This approach targets multiple metabolic pathways simultaneously and may have synergistic benefits.

🔬 PEARL #3: Microbiome-Immunometabolism Axis

The gut microbiome produces metabolites (short-chain fatty acids like butyrate) that profoundly influence immune cell metabolism. Butyrate promotes Treg differentiation via OXPHOS enhancement. Strategies to preserve microbiome diversity (judicious antibiotics, consider probiotics/prebiotics) may support beneficial immunometabolic programming.

Integrating Immunometabolism into Clinical Practice

Biomarkers of Metabolic Dysfunction

Currently, bedside assessment of immune cell metabolism is not routine, but candidate biomarkers include:

Systemic Markers:

Lactate (reflects glycolytic flux but non-specific)
Lactate/pyruvate ratio (indicates OXPHOS dysfunction)
Ketone bodies (reflect FAO and metabolic stress)
Acylcarnitines (intermediates of FAO; accumulation suggests impaired oxidation)

Research Tools Moving Toward Bedside:

Flow cytometry for GLUT1 expression on immune cells
Seahorse metabolic flux assays (measuring oxygen consumption and glycolysis in real-time)
Metabolomics profiling (plasma metabolites reflecting pathway activity)
Mitochondrial function assays

Functional Immunometabolic Profiling:

Theratests measuring immune cell metabolic capacity (e.g., maximum glycolytic capacity, respiratory reserve) could stratify patients:

Hyperinflammatory phenotype: High glycolysis, low OXPHOS → glycolysis inhibitors
Immunosuppressed phenotype: Low glycolysis and OXPHOS → metabolic support, immune stimulation

Precision Medicine Approach

Patient Stratification:

Not all critically ill patients will benefit from the same metabolic intervention. Subphenotyping based on:

Inflammatory markers (CRP, IL-6)
Metabolic markers (lactate, glucose, amino acids)
Immune cell profiles (HLA-DR expression on monocytes, lymphocyte counts)
Clinical trajectory (early vs. late sepsis, resolving vs. persistent inflammation)

Intervention Timing:

Early phase (0-72 hours): Hyperinflammation predominates; glycolysis inhibitors or AMPK activators may help
Late phase (>72 hours): Immunosuppression emerges; metabolic support to restore function may be needed

Combination Therapies:

Single-target approaches may fail due to metabolic redundancy. Combining:

Metabolic modulators (metformin)
Immunonutrition (omega-3s, glutamine)
Mitochondrial protectants (CoQ10, thiamine, vitamin C)
Microbiome support

Future Directions

Pharmacological Advances:

Specific enzyme inhibitors (targeting key metabolic nodes)
SPM analogs (stable resolvins, protectins)
Mitochondrial transplantation or mitochondrial-targeted therapies
Gene therapy to enhance metabolic flexibility

Nutritional Advances:

Designer enteral formulas based on individual metabolic profiling
Timed nutrient delivery (chrononutrition) aligned with circadian metabolic rhythms
Isotope tracing in patients to track nutrient fate in real-time

Technology Integration:

Continuous metabolic monitoring (wearable or bedside devices)
Artificial intelligence predicting metabolic trajectories
Point-of-care metabolomics

💊 HACK #3: The Thiamine-Vitamin C-Hydrocortisone Connection

While the Marik protocol (high-dose vitamin C, thiamine, hydrocortisone) has not been definitively proven in large RCTs, the metabolic rationale is sound: thiamine is essential for mitochondrial OXPHOS (TCA cycle), vitamin C supports mitochondrial function and immune cell activity, and hydrocortisone modulates excessive inflammation. In refractory septic shock with suspected vitamin deficiencies, this combination may have metabolic benefits beyond the anti-inflammatory effects.

Conclusion

Immunometabolism represents a fundamental reframing of critical illness pathophysiology. The recognition that immune cell function is dictated by metabolic programming opens a vast therapeutic landscape. Metabolic reprogramming is not simply a consequence of critical illness but a driver of immune dysfunction, organ failure, and mortality.

The shift from oxidative phosphorylation to glycolysis during immune activation is a purposeful adaptation enabling rapid effector functions but comes at the cost of sustained energy deficits and impaired resolution responses. Therapeutically targeting this metabolic switch—using repurposed drugs like metformin, precision immunonutrition with glutamine and omega-3 fatty acids, and novel metabolic modulators—offers promise.

However, complexity is the rule: metabolic interventions have context-dependent effects, with potential benefits in some patients and harm in others. The future lies in precision immunometabolic medicine—stratifying patients based on metabolic and immune profiles, timing interventions appropriately, and combining therapies to address the multifaceted nature of critical illness.

As we move forward, several principles should guide practice and research:

Measure, don't assume: Metabolic dysfunction is heterogeneous; bedside metabolic profiling is needed
Context matters: Early versus late, hyperinflammatory versus immunosuppressed
Think beyond calories: Nutrition is information, not just fuel
Target multiplicity: Single interventions may fail; rational combinations are necessary
Mitochondria matter: Protecting and restoring mitochondrial function is central

The immunometabolism of critical illness bridges fundamental immunology, biochemistry, and clinical practice. For the intensivist, understanding these principles transforms how we approach nutrition, metabolic management, and immunomodulation—offering hope for improving outcomes in our most vulnerable patients.

Key Take-Home Points

Immune cell metabolism drives function: Glycolysis supports pro-inflammatory responses (M1, Teff), while OXPHOS supports anti-inflammatory and resolution responses (M2, Treg).
Metabolic dysfunction in critical illness is bidirectional: Early glycolytic overdrive contributes to hyperinflammation; later inability to sustain metabolism leads to immunosuppression.
Metformin is a promising immunometabolic modulator: AMPK activation may restore metabolic balance, but clinical trials are ongoing.
Glutamine's role is nuanced: Depletion impairs immunity, but high-dose supplementation may harm; precision supplementation guided by measurement is needed.
Omega-3 fatty acids promote resolution: Via SPM generation and metabolic reprogramming toward OXPHOS, but patient selection and timing are critical.
Precision medicine is the future: One-size-fits-all approaches fail; metabolic and immune profiling will guide individualized therapy.

References

O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553-565.
Cheng SC, Scicluna BP, Arts RJW, et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol. 2016;17(4):406-413.
Mills EL, Kelly B, Logan A, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2016;167(2):457-470.
Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013;496(7444):238-242.
Loftus RM, Finlay DK. Immunometabolism: Cellular metabolism turns immune regulator. J Biol Chem. 2016;291(1):1-10.
Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38(4):633-643.
Buck MD, O'Sullivan D, Klein Geltink RI, et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell. 2016;166(1):63-76.
van Wyngene L, Vandewalle J, Libert C. Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last? EMBO Mol Med. 2018;10(8):e8712.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-874.
Elenkov IJ, Iezzoni DG, Daly A, et al. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation. 2005;12(5):255-269.
Cameron MJ, Kelvin DJ. Cytokine storm syndrome. In: Mackay IR, Rose NR, eds. The Autoimmune Diseases. 5th ed. Academic Press; 2014:965-978.
Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25(7):771-784.
Galván-Peña S, O'Neill LA. Metabolic reprogramming in macrophage polarization. Front Immunol. 2014;5:420.
Michalek RD, Gerriets VA, Jacobs SR, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186(6):3299-3303.
Shi LZ, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011;208(7):1367-1376.
Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5(1):66-72.
Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360(9328):219-223.
Piel DA, Gruber PJ, Weinheimer CJ, et al. Mitochondrial resuscitation with exogenous cytochrome c in the septic heart. Crit Care Med. 2007;35(9):2120-2127.
Joffre J, Hellman J, Ince C, Ait-Oufella H. Endothelial responses in sepsis. Am J Respir Crit Care Med. 2020;202(3):361-370.
Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol. 2012;12(7):503-516.
Cameron AM, Lawless SJ, Pearce EJ. Metabolism and acetylation in innate immune cell function and fate. Semin Immunol. 2016;28(5):408-416.
Infantino V, Convertini P, Cucci L, et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem J. 2011;438(3):433-436.
Palsson-McDermott EM, Curtis AM, Goel G, et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015;21(1):65-80.
Lampropoulou V, Sergushichev A, Bambouskova M, et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab. 2016;24(1):158-166.
Mills EL, Ryan DG, Prag HA, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature. 2018;556(7699):113-117.
Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559-563.
Pucino V, Certo M, Bulusu V, et al. Lactate buildup at the site of chronic inflammation promotes disease by inducing CD4+ T cell metabolic rewiring. Cell Metab. 2019;30(6):1055-1074.
Haas R, Smith J, Rocher-Ros V, et al. Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions. PLoS Biol. 2015;13(7):e1002202.
Ratter JM, Rooijackers HMM, Hooiveld GJ, et al. In vitro and in vivo effects of lactate on metabolism and cytokine production of human primary PBMCs and monocytes. Front Immunol. 2018;9:2564.
Angelin A, Gil-de-Gómez L, Dahiya S, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 2017;25(6):1282-1293.
Wang R, Dillon CP, Shi LZ, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35(6):871-882.
Gerriets VA, Kishton RJ, Nichols AG, et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest. 2015;125(1):194-207.
Berod L, Friedrich C, Nandan A, et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 2014;20(11):1327-1333.
Howie D, Cobbold SP, Adams E, et al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight. 2017;2(3):e89160.
Cameron AM, Castoldi A, Sanin DE, et al. Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species-mediated DNA damage. Nat Immunol. 2019;20(4):420-432.
Langley RJ, Tsalik EL, van Velkinburgh JC, et al. An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med. 2013;5(195):195ra95.
Eckerle M, Ambroggio L, Pushing T, et al. Metabolomics as a driver in advancing precision medicine in sepsis. Pharmacotherapy. 2017;37(9):1023-1032.
Howell GM, Gomez H, Collage RD, et al. Augmenting autophagy to treat acute kidney injury during endotoxemia in mice. PLoS One. 2013;8(7):e69520.
Escobar DA, Botero-Quintero AM, Kautza BC, et al. Adenosine monophosphate-activated protein kinase activation protects against sepsis-induced organ injury and inflammation. J Surg Res. 2015;194(1):262-272.
Drosatos K, Khan RS, Trent CM, et al. Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice. Circ Heart Fail. 2013;6(3):550-562.
Ding HG, Li FF, Zhang L, et al. The effect of metformin on mortality and complications of sepsis: A systematic review and meta-analysis. Front Pharmacol. 2022;13:805981.
Liang H, Ding X, Li L, et al. Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies. Crit Care. 2019;23(1):50.
Doenyas-Barak K, Beberashvili I, Marcus R, et al. Lactic acidosis and severe septic shock in metformin users: A cohort study. Emerg Med J. 2016;33(6):386-390.
Calzada Gutiérrez S, Parra Ramírez LM, Moreno JM, et al. Metformin for critically ill patients: Review of the evidence and perspectives. Med Intensiva. 2018;42(5):318-324.
Romero R, Erez O, Hüttemann M, et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol. 2017;217(3):282-302.
El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223-228.
Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542-546.
Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253-270.
Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-1174.
Eikawa S, Nishida M, Mizukami S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112(6):1809-1814.
Ursini F, Russo E, Pellino G, et al. Metformin and autoimmunity: A "new deal" of an old drug. Front Immunol. 2018;9:1236.
Corcoran SE, O'Neill LA. HIF1α and metabolic reprogramming in inflammation. J Clin Invest. 2016;126(10):3699-3707.
Kelly B, Tannahill GM, Murphy MP, O'Neill LA. Metformin inhibits the production of reactive oxygen species from NADH:ubiquinone oxidoreductase to limit induction of interleukin-1β (IL-1β) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. J Biol Chem. 2015;290(33):20348-20359.
Jha AK, Huang SC, Sergushichev A, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42(3):419-430.
Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37-51.
Stacpoole PW, Nagaraja NV, Hutson AD. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol. 2003;43(7):683-691.
Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med. 1992;327(22):1564-1569.
Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra34.
Wang Y, Huang Y, Guan F, et al. Hypoxia-inducible factor-1α and MAPK co-regulate activation of hepatic stellate cells upon hypoxia stimulation. PLoS One. 2013;8(9):e74051.
Bambouskova M, Gorvel L, Lampropoulou V, et al. Electrophilic properties of itaconate and derivatives regulate the IκBζ-ATF3 inflammatory axis. Nature. 2018;556(7702):501-504.
Hooftman A, Angiari S, Hester S, et al. The immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome activation. Cell Metab. 2020;32(3):468-478.
Weichhart T, Hengstschläger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15(10):599-614.
Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39-68.
Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460(7251):108-112.
Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009;30(6):832-844.
Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci. 2015;1346(1):33-44.
Newsholme P, Procopio J, Lima MM, et al. Glutamine and glutamate—their central role in cell metabolism and function. Cell Biochem Funct. 2003;21(1):1-9.
Newsholme P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr. 2001;131(9 Suppl):2515S-2522S.
Cruzat V, Macedo Rogero M, Noel Keane K, et al. Glutamine: Metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10(11):1564.
Parry-Billings M, Evans J, Calder PC, Newsholme EA. Does glutamine contribute to immunosuppression after major burns? Lancet. 1990;336(8714):523-525.
Oudemans-van Straaten HM, Bosman RJ, Treskes M, et al. Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med. 2001;27(1):84-90.
Wischmeyer PE, Dhaliwal R, McCall M, et al. Parenteral glutamine supplementation in critical illness: a systematic review. Crit Care. 2014;18(2):R76.
Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013;368(16):1489-1497.
van Zanten AR, Sztark F, Kaisers UX, et al. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA. 2014;312(5):514-524.
Stehle P, Ellger B, Kojic D, et al. Glutamine dipeptide-supplemented parenteral nutrition improves the clinical outcomes of critically ill patients: A systematic evaluation of randomised controlled trials. Clin Nutr ESPEN. 2017;17:75-85.
Novak F, Heyland DK, Avenell A, et al. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med. 2002;30(9):2022-2029.
Wischmeyer PE. Glutamine: role in critical illness and ongoing clinical trials. Curr Opin Gastroenterol. 2008;24(2):190-197.
Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101.
Serhan CN, Chiang N, Dalli J, Levy BD. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol. 2014;7(2):a016311.
Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40(3):315-327.
Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7):612-619.
Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood. 2012;120(15):e60-e72.
Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015;1851(4):469-484.
Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105-1115.
Pontes-Arruda A, Aragão AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006;34(9):2325-2333.
Gadek JE, DeMichele SJ, Karlstad MD, et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit Care Med. 1999;27(8):1409-1420.
Singer P, Shapiro H, Theilla M, et al. Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 2008;34(9):1580-1592.
Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011;306(14):1574-1581.
Rice TW, Wheeler AP, Thompson BT, et al. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA. 2012;307(8):795-803.
Manzanares W, Langlois PL, Dhaliwal R, et al. Intravenous fish oil lipid emulsions in critically ill patients: an updated systematic review and meta-analysis. Crit Care. 2015;19:167.
Calder PC, Waitzberg DL, Klek S, Martindale RG. Lipids in parenteral nutrition: biological aspects. JPEN J Parenter Enteral Nutr. 2020;44 Suppl 1:S21-S27.
Morris CR, Hamilton-Reeves J, Martindale RG, et al. Acquired amino acid deficiencies: a focus on arginine and glutamine. Nutr Clin Pract. 2017;32(1_suppl):30S-47S.
Luiking YC, Poeze M, Dejong CH, et al. Sepsis: an arginine deficiency state? Crit Care Med. 2004;32(10):2135-2145.
Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568-1573.
Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641-654.
Gianotti L, Braga M, Nespoli L, et al. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology. 2002;122(7):1763-1770.
Drover JW, Dhaliwal R, Weitzel L, et al. Perioperative use of arginine-supplemented diets: a systematic review of the evidence. J Am Coll Surg. 2011;212(3):385-399.
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770-1773.
Amrein K, Schnedl C, Holl A, et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA. 2014;312(15):1520-1530.
Amrein K, Parekh D, Westphal S, et al. Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study). BMJ Open. 2019;9(11):e031083.
Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50(3):194-200.
Bikle DD, Christakos S. New aspects of vitamin D metabolism and action—addressing the skin as source and target. Nat Rev Endocrinol. 2020;16(4):234-252.
Latic N, Erben RG. Vitamin D and cardiovascular disease, with emphasis on hypertension, atherosclerosis, and heart failure. Int J Mol Sci. 2020;21(18):6483.
Ryan PM, Caplice NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity (Silver Spring). 2020;28(7):1191-1194.
Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48-79.
McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.
Preiser JC, van Zanten AR, Berger MM, et al. Metabolic and nutritional support of critically ill patients: consensus and controversies. Crit Care. 2015;19:35.
Marik PE, Khangoora V, Rivera R, et al. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151(6):1229-1238.
Fowler AA III, Truwit JD, Hite RD, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322(13):1261-1270.
Fujii T, Luethi N, Young PJ, et al. Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial. JAMA. 2020;323(5):423-431.
Moskowitz A, Huang DT, Hou PC, et al. Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: the ACTS randomized clinical trial. JAMA. 2020;324(7):642-650.
Donnino MW, Andersen LW, Chase M, et al. Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: a pilot study. Crit Care Med. 2016;44(2):360-367.
Woolum JA, Abner EL, Kelly A, et al. Effect of thiamine administration on lactate clearance and mortality in patients with septic shock. Crit Care Med. 2018;46(11):1747-1752.

Glossary of Key Terms

AMPK (AMP-activated protein kinase): Cellular energy sensor activated by low ATP/AMP ratio; promotes catabolic pathways and mitochondrial biogenesis.

Efferocytosis: Process by which phagocytes remove apoptotic cells; critical for inflammation resolution.

FAO (Fatty acid oxidation): β-oxidation of fatty acids in mitochondria to generate acetyl-CoA for the TCA cycle.

HIF-1α (Hypoxia-inducible factor-1α): Transcription factor stabilized under hypoxia (or pseudohypoxia) that drives glycolytic gene expression.

Immunometabolism: The study of metabolic pathways in immune cells and their regulation of immune function.

mTOR (Mechanistic target of rapamycin): Serine/threonine kinase that integrates nutrient, growth factor, and energy signals to control cell growth and metabolism.

OXPHOS (Oxidative phosphorylation): ATP generation via the electron transport chain in mitochondria; efficient but slower energy production.

PPP (Pentose phosphate pathway): Metabolic pathway parallel to glycolysis generating NADPH and ribose-5-phosphate.

SPMs (Specialized pro-resolving mediators): Lipid mediators (resolvins, protectins, maresins) derived from omega-3 fatty acids that actively promote resolution of inflammation.

TCA cycle (Tricarboxylic acid cycle): Also called Krebs cycle or citric acid cycle; central metabolic pathway oxidizing acetyl-CoA to generate reducing equivalents for OXPHOS.

Acknowledgments

The authors acknowledge the pioneering work of researchers in immunometabolism who have transformed our understanding of immune cell biology and opened new therapeutic horizons for critical care medicine.

Conflict of Interest Statement: The authors declare no conflicts of interest related to this manuscript.

Funding: No specific funding was received for this review article.

Monday, November 10, 2025

The Endotype-Driven Sepsis Trial: A New Research Paradigm

The Endotype-Driven Sepsis Trial: A New Research Paradigm

Abstract

Introduction

Moving Beyond "One-Size-Fits-All" Trials: Why Previous Sepsis Drug Trials Failed and How Endotypes Change the Game

The Historical Landscape of Failure

Why Did These Trials Fail?

The Endotype Solution

Evidence for Endotype-Specific Effects

Platform Trials: Designing Adaptive Studies That Can Test Multiple Therapies Against Different Sepsis Subphenotypes Simultaneously

The Platform Trial Revolution

Key Features of Platform Trials

Real-World Examples

Statistical Innovations

Challenges and Solutions

Biomarker-Enriched Enrollment: Selecting Patients for Trials Based on Inflammatory or Immunosuppressive Profiles, Not Just Clinical Criteria

The Rationale for Biomarker Enrichment

Categories of Sepsis Biomarkers

Practical Implementation

Case Studies in Biomarker-Enriched Trials

Challenges in Biomarker Implementation

Emerging Technologies

Practical Pearls for Critical Care Trainees

Oysters: Common Misconceptions

Future Directions

Conclusion

References

Key Take-Home Messages for Postgraduate Trainees

A Vision for 2030

Final Thoughts

Recommended Further Reading

The Microcirculation as the Ultimate Resuscitation Endpoint: A Paradigm Shift in Critical Care

The Microcirculation as the Ultimate Resuscitation Endpoint: A Paradigm Shift in Critical Care

Abstract

Introduction

Handheld Vital Microscopy: Window to the Microcirculation

Historical Evolution and Technical Principles

Image Acquisition and Analysis

Clinical Validation and Prognostic Value

Hemodynamic Coherence: Bridging Macro and Microcirculation

Defining the Concept

Mechanisms of Hemodynamic Incoherence

Clinical Evidence of Incoherence

The Coherence Spectrum

Microcirculation-Guided Therapy: Translating Knowledge to Practice

Conceptual Framework

Fluid Resuscitation Strategies

Vasopressor Optimization

Adjunctive Microcirculatory Interventions

Clinical Implementation: The 3M Approach

Limitations and Future Directions

Current Limitations

Emerging Technologies

Research Priorities

Conclusion

Key References

The Immunometabolism of Critical Illness: Bridging Metabolism and Immune Function in the ICU

The Immunometabolism of Critical Illness: Bridging Metabolism and Immune Function in the ICU

Abstract

Introduction

How Immune Cell Metabolism Drives Function: The Shift from Oxidative Phosphorylation to Glycolysis

The Warburg Effect Revisited: From Cancer to Immunity

Metabolic Phenotypes Define Immune Cell Function

T Cell Metabolic Programming

Metabolic Dysfunction in Critical Illness: A Vicious Cycle

🔬 PEARL #1: The Succinate-HIF-1α Axis

🦪 OYSTER #1: Not All Glycolysis Is Pro-inflammatory

Metabolic Reprogramming as Therapy: Targeting Immune Cell Metabolism to Modulate Inflammation

Metformin: Beyond Glucose Control

Other Metabolic Modulators

💊 HACK #1: Metformin as Sepsis Prophylaxis?

🔬 PEARL #2: Timing Matters

Nutrigenomics: How Specific Nutrients Signal Immune Cells

Glutamine: The Conditionally Essential Immunonutrient

Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs): Specialized Pro-resolving Mediators

Arginine: The Precursor of Nitric Oxide and Polyamines

Vitamin D: Immunometabolic Regulator

🦪 OYSTER #2: The Omega-3 Heterogeneity

💊 HACK #2: The "Immunonutrition Bundle"